Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation
Jin Zhou,Qi Qu,Suning Chen,Yang Xu,Hongjie Shen,J. Cen,Depei Wu
DOI: https://doi.org/10.3109/10428194.2015.1023721
2015-02-27
Abstract:Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the BCR–ABL fusion gene, resulting from the so-called Philadelphia chromosome (a reciprocal translocation between chromosomes 9 and 22). This translocation leads to constitutive activation of ABL protein as a tyrosine kinase enzyme, which subsequently affects cell differentiation, proliferation and apoptosis [1]. The emergence of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, has significantly improved the prognosis of CML. However, resistance to TKIs occurs in many patients with mutations in the ABL tyrosine kinase domain (KD). In practice, molecular monitoring and mutational analysis may help to identify these patients and guide adjustment of therapies if necessary [2]. Here we present a rare case of CML harboring dynamic clonal evolution from E255K (soft tissue mass) to T315I (peripheral blood, PB), in whom a major molecular response (MMR) was achieved with TKI therapy. A 61-year-old Chinese male was admitted to our hospital in April 2013, with the complaint of a chest wall mass located on the left inferior sternum and radiating pain along the ribs. Physical examination revealed a tender chest mass of low mobility and obscure boundary with size 6 cm 4 cm on the left inferior sternum, and splenomegaly was also observed to 5 cm below the left costal margin. Examination of the PB indicated a high white blood cell count of 30.65 109/L, a platelet count of 115 109/L and a hemoglobin level of 139 g/L. Bone marrow (BM) aspiration revealed hyperactive proliferation and granulocytic hyperplasia (89% of nucleated cells). Cytogenetic analysis of BM cells showed an abnormal karyotype of 46,XY,t(9;22)(q34;q11)[20]. Reverse-transcription polymerase chain reaction (RT-PCR) detected BCR–ABL gene transcripts (b2a2/b3a2) in the PB, without any detectable mutations of the ABL KD. Further quantitative analysis (QPCR) of BCR–ABL/ABL indicated that the BCR–ABL transcript was at a level of 46.89% (International Scale, IS). Due to his rejective attitude towards lumpectomy and biopsy of the chest mass, this patient was diagnosed as chronic phase (CP)-CML with intermediate risk according to Sokal sore 0.84 and Hasford score 1163 [3,4]. Upon diagnosis, imatinib (Novartis Pharmaceuticals) 400 mg daily was administered to the patient and a hematological response was rapidly achieved 10 days later, which has remained until now. The BCR–ABL transcript level was apparently decreased to 8.84% (IS) after 1 month of initial therapy. However, BCR–ABL transcript increased to 12.57% (IS) 3 months later. In September, lumpectomy and biopsy were performed due to an enlarged chest mass [Figure 1(A)]. Myeloperoxidase (MPO), KP-1, Bcl-2, CD43 and Ki-67 (30%) were positive by immunohistochemistry, and the BCR–ABL fusion gene was detected by dual-color fluorescence in situ hybridization (FISH) in a paraffin-embedded tissue section [Figure 1(B)]. Some 57.24% (IS) of BCR–ABL transcript was detected and E255K mutation of the ABL gene was found in the biopsy tissue [Figure 1(C)]. Considering that this mutation could be resistant to imatinib, dasatinib (Bristol-Myers Squibb) 100 mg daily was then substituted for imatinib. Optimal molecular response (IS: 4.05%) was observed in October. However, this was lost again (IS: 17.57%) at the 3-month monitoring, and T315I mutation was found in the PB sample [Figure 1(D)]. Meanwhile, this patient had systemic symptoms such as fever, periodontal pain and wrist swelling. Nilotinib (Novartis Pharmaceuticals) 800 mg daily was subsequently administered in an effort to overcome the TKI resistance. After 3 months’ treatment, this patient recovered from his systemic symptoms and the BCR–ABL/ABL transcript level in a PB sample was 0.05% (IS) without any detectable ABL KD mutation [Figure 1(E)]. Moreover, FISH analysis demonstrated negativity (1/400) for the BCR–ABL fusion gene. Therefore, a MMR was achieved and a persistent response to nilotinib has remained for 6 months at the time of this report. T315I mutation, “gatekeeper” in the ABL KD and affecting TKI binding, is of particular concern regarding its resistance to both firstand second-generation TKIs.